Current and emerging therapies for localized high-risk prostate cancer

Published on Mar 4, 2021in Expert Review of Anticancer Therapy3.573
· DOI :10.1080/14737140.2021.1852932
Lisa Moris11
Estimated H-index: 11
(Katholieke Universiteit Leuven),
Gaëtan Devos10
Estimated H-index: 10
(Katholieke Universiteit Leuven)
+ 10 AuthorsSteven Joniau73
Estimated H-index: 73
(Katholieke Universiteit Leuven)
Introduction: Despite progress in the field of high-risk localized prostate cancer (HRPCa) treatments, high-risk patients treated with curative intent are at increased risk of biochemical recurrenc...
#1Andrew Kneebone (USYD: University of Sydney)H-Index: 29
Last. Maria PearseH-Index: 9
view all 23 authors...
Summary Background Adjuvant radiotherapy has been shown to halve the risk of biochemical progression for patients with high-risk disease after radical prostatectomy. Early salvage radiotherapy could result in similar biochemical control with lower treatment toxicity. We aimed to compare biochemical progression between patients given adjuvant radiotherapy and those given salvage radiotherapy. Methods We did a phase 3, randomised, controlled, non-inferiority trial across 32 oncology centres in Aus...
52 CitationsSource
#1James A. Eastham (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 107
#2Glenn Heller (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 94
Last. Michael J. Morris (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 66
view all 20 authors...
PURPOSERadical prostatectomy (RP) alone is often inadequate in curing men with clinically localized, high-risk prostate cancer (PC). We hypothesized that chemohormonal therapy (CHT) with androgen-d...
11 CitationsSource
#1Charlien Berghen (Katholieke Universiteit Leuven)H-Index: 6
#2Steven Joniau (Katholieke Universiteit Leuven)H-Index: 73
Last. Gert De Meerleer (Katholieke Universiteit Leuven)H-Index: 36
view all 8 authors...
Radical prostatectomy is a well-established treatment option in the management of localized and locally advanced prostate cancer. An extended lymphadenectomy is performed in case of substantial risk for lymph node involvement. When biochemical recurrence (BCR) occurs, salvage radiotherapy (SRT) is performed. The benefit in terms of BCR-free survival (FS) and metastasis-FS by adding 6 months of androgen deprivation therapy (ADT) compared with SRT only has already been established. Retrospective e...
1 CitationsSource
PURPOSEGermline testing (GT) is a central feature of prostate cancer (PCA) treatment, management, and hereditary cancer assessment. Critical needs include optimized multigene testing strategies tha...
57 CitationsSource
#1William C. Jackson (UM: University of Michigan)H-Index: 16
#2Holly E. Hartman (UM: University of Michigan)H-Index: 8
Last. Daniel E. Spratt (UM: University of Michigan)H-Index: 50
view all 23 authors...
PURPOSEIn men with localized prostate cancer, the addition of androgen-deprivation therapy (ADT) or a brachytherapy boost (BT) to external beam radiotherapy (EBRT) have been shown to improve variou...
7 CitationsSource
#1Lisa Moris (Katholieke Universiteit Leuven)H-Index: 11
#2Marcus G. Cumberbatch (University of Sheffield)H-Index: 15
Last. Thomas WiegelH-Index: 50
view all 32 authors...
Abstract Context The optimal treatment for men with high-risk localized or locally advanced prostate cancer (PCa) remains unknown. Objective To perform a systematic review of the existing literature on the effectiveness of the different primary treatment modalities for high-risk localized and locally advanced PCa. The primary oncological outcome is the development of distant metastases at ≥5 yr of follow-up. Secondary oncological outcomes are PCa-specific mortality, overall mortality, biochemica...
40 CitationsSource
#1Johann S. de BonoH-Index: 124
#2Joaquin MateoH-Index: 37
Last. Maha Hussain (NU: Northwestern University)H-Index: 78
view all 20 authors...
BACKGROUND: Multiple loss-of-function alterations in genes that are involved in DNA repair, including homologous recombination repair, are associated with response to poly(adenosine diphosphate-ribose) polymerase (PARP) inhibition in patients with prostate and other cancers. METHODS: We conducted a randomized, open-label, phase 3 trial evaluating the PARP inhibitor olaparib in men with metastatic castration-resistant prostate cancer who had disease progression while receiving a new hormonal agen...
373 CitationsSource
#1Michael S. Hofman (University of Melbourne)H-Index: 44
#2Nathan Lawrentschuk (University of Melbourne)H-Index: 58
Last. Declan G. Murphy (University of Melbourne)H-Index: 107
view all 26 authors...
Summary Background Conventional imaging using CT and bone scan has insufficient sensitivity when staging men with high-risk localised prostate cancer. We aimed to investigate whether novel imaging using prostate-specific membrane antigen (PSMA) PET-CT might improve accuracy and affect management. Methods In this multicentre, two-arm, randomised study, we recruited men with biopsy-proven prostate cancer and high-risk features at ten hospitals in Australia. Patients were randomly assigned to conve...
298 CitationsSource
#1Joaquin Mateo (Hebron University)H-Index: 37
#2George Seed (ICR: Institute of Cancer Research)H-Index: 19
Last. Johann S. de BonoH-Index: 124
view all 35 authors...
The genomics of primary prostate cancer differ from those of metastatic castration-resistant prostate cancer (mCRPC). We studied genomic aberrations in primary prostate cancer biopsies from patients who developed mCRPC, also studying matching, same-patient, diagnostic, and mCRPC biopsies following treatment. We profiled 470 treatment-naive prostate cancer diagnostic biopsies and, for 61 cases, mCRPC biopsies, using targeted and low-pass whole-genome sequencing (n = 52). Descriptive statistics we...
60 CitationsSource
#1Jeffrey J. Tosoian (UM: University of Michigan)H-Index: 29
#2S. Birer (UM: University of Michigan)H-Index: 2
Last. Daniel E. Spratt (UM: University of Michigan)H-Index: 50
view all 27 authors...
Prostate cancer exhibits biological and clinical heterogeneity even within established clinico-pathologic risk groups. The Decipher genomic classifier (GC) is a validated method to further risk-stratify disease in patients with prostate cancer, but its performance solely within National Comprehensive Cancer Network (NCCN) high-risk disease has not been undertaken to date. A multi-institutional retrospective study of 405 men with high-risk prostate cancer who underwent primary treatment with radi...
4 CitationsSource
Cited By1
#1Daimantas MilonasH-Index: 8
#2Z. VenclovasH-Index: 3
Last. Tomas RuzgasH-Index: 4
view all 4 authors...
OBJECTIVE To assess the significance of prostate-specific antigen (PSA) persistence at the first measurement after radical prostatectomy (RP) on long-term outcomes in different prostate cancer risk groups. METHODS Persistent PSA was defined as ≥0.1 ng/mL at 4-8 weeks after RP. Patients were stratified into low-, intermediate- and high-risk groups, according to the preoperative PSA, pathological stage, grade group and lymph nodes status. The ten-year cumulative incidence of biochemical recurrence...